1 – 39 of 39
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes
(
- Contribution to journal › Article
-
Mark
Clinical performance and robustness evaluation of plasma amyloid-β42/40 prescreening
(
- Contribution to journal › Article
-
Mark
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Sex differences in blood biomarkers and cognitive performance in individuals with autosomal dominant Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
(
- Contribution to journal › Article
- 2022
-
Mark
Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease–related blood-based biomarkers : Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group
(
- Contribution to journal › Article
-
Mark
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau
(
- Contribution to journal › Article
- 2021
-
Mark
The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau
(
- Contribution to journal › Article
-
Mark
Association between serum urate and CSF markers of Alzheimer's disease pathology in a population-based sample of 70-year-olds
(
- Contribution to journal › Article
-
Mark
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers
(
- Contribution to journal › Article
- 2020
-
Mark
Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF
(
- Contribution to journal › Article
-
Mark
Quantification of total apolipoprotein e and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases
(
- Contribution to journal › Article
-
Mark
Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Propagation of Tau Pathology : Integrating Insights From Postmortem and In Vivo Studies
(
- Contribution to journal › Scientific review
-
Mark
Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration : A translatable marker of synaptic degeneration
(
- Contribution to journal › Article
- 2019
-
Mark
Cerebrospinal fluid concentrations of extracellular matrix proteins in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals
(
- Contribution to journal › Article
-
Mark
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays : Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid
(
- Contribution to journal › Article
-
Mark
Method comparison study of the Elecsys® β-Amyloid (1–42) CSF assay versus comparator assays and LC-MS/MS
(
- Contribution to journal › Article
-
Mark
Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease : Cross-validation study of practical algorithms
(
- Contribution to journal › Article
- 2018
-
Mark
Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Update on biomarkers for amyloid pathology in Alzheimer's disease
(
- Contribution to journal › Scientific review
-
Mark
No association of salivary total tau concentration with Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Biology/Disease-Driven Initiative on Protein-Aggregation Diseases of the Human Proteome Project : Goals and Progress to Date
(
- Contribution to journal › Article
-
Mark
Apolipoprotein E genotypes and longevity across dementia disorders
(
- Contribution to journal › Article
-
Mark
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease
(
- Contribution to journal › Article
- 2017
-
Mark
CSF/serum albumin ratio in dementias : a cross-sectional study on 1861 patients
(
- Contribution to journal › Article
-
Mark
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
(
- Contribution to journal › Article
-
Mark
Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers
(
- Contribution to journal › Article
- 2016
-
Mark
Reference measurement procedure for CSF amyloid beta (Aβ)1–42 and the CSF Aβ1–42/Aβ1–40 ratio – a cross-validation study against amyloid PET
(
- Contribution to journal › Article
-
Mark
The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease
(
- Contribution to journal › Article
- 2013
-
Mark
Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease
(
- Contribution to journal › Article
- 2011
-
Mark
Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population
(
- Contribution to journal › Article